Immunohistochemical evaluation of MYC expression in mantle cell lymphoma
Article first published online: 8 AUG 2013
© 2013 John Wiley & Sons Ltd
Volume 63, Issue 4, pages 499–508, October 2013
How to Cite
2013) Histopathology 63, 499–508 Immunohistochemical evaluation of MYC expression in mantle cell lymphoma, , , , , , , , & (
- Issue published online: 16 SEP 2013
- Article first published online: 8 AUG 2013
- Accepted manuscript online: 17 JUN 2013 03:02AM EST
- Manuscript Accepted: 12 JUN 2013
- Manuscript Received: 4 MAR 2013
- University of Wisconsin Carbone Cancer Center. Grant Number: P30 CA014520
- National Center for Research Resources. Grant Number: 1UL1RR025011
- National Center for Advancing Translational Sciences. Grant Number: 9U54TR000021
- mantle cell lymphoma;
- MYC ;
- tissue microarray
To assess the validity and potential clinical utility of evaluating MYC expression by immunohistochemistry (IHC) in mantle cell lymphoma (MCL).
Methods and results
MYC IHC was scored on a tissue microarray containing 62 MCLs and 29 controls by two pathologists. Inter-observer correlation was high (intra-class correlation of 0.98). MYC IHC scores correlated with MYC expression (Spearman's rank correlation 0.69, P < 0.0001) and weakly with Ki67 proliferation index (Spearman's rank correlation 0.30, P = 0.03). Six blastic MCLs did not have higher mean MYC IHC scores or MYC mRNA expression than non-blastic MCLs. None of 57 cases assessed, including all of the blastic cases, showed MYC rearrangement by fluorescence in-situ hybridization. Multivariate analysis with backward selection from potential predictors including age, lactate dehydrogenase, leukocyte count, MIPI score, ECOG performance status, blastic morphology and Ki67 index showed that MYC IHC score is an independent predictor of progression-free survival (hazard ratio 2.34, 95% CI 1.42–3.88, P = 0.0009) and overall survival (hazard ratio 1.90, 95% CI 1.05–3.43, P = 0.034).
We show that a new monoclonal anti-MYC antibody can enable accurate and reproducible visual assessment of MYC expression that is independently predictive of clinical outcomes in MCL.